No Data
No Data
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Express News | Chemomab Therapeutics Announces Late-Breaking Oral Presentation of Cm-101 Phase 2 Results in Primary Sclerosing Cholangitis at Aasld the Liver Meeting® 2024
Chemomab Therapeutics Announces Shareholder Meeting
Express News | Carl L. Gordon Reports 9.99% Stake in Chemomab Therapeutics as of Sept 12 Vs 16.0% as Reported in March 11 - SEC Filing
ADRs Close Lower; Chemomab Therapeutics Ltd. Declines 17%
No Data
No Data